Answers are grounded in this paper and cite their sources.
This review uncovers N6-methyladenosine's role in apoptosis and cellular pathways in ocular diseases, indicating new therapeutic targets.
N6-methyladenosine (m6A), a pivotal RNA modification, has garnered considerable attention in cell biology and disease research. m6A plays a critical role in the regulation of gene expression, cell proliferation, differentiation, and apoptosis, with particular relevance to the onset and progression of ocular diseases. This review examines the current research on m6A in ocular diseases, including keratitis, cataracts, glaucoma, retinopathy, thyroid ophthalmopathy, and ocular tumors, highlighting its functional significance and potential mechanisms in these conditions. Recent studies suggest that m6A modification influences cellular fate and pathophysiological processes by modulating the expression of key genes. However, a deeper understanding of the precise mechanisms underlying m6A action in ocular diseases is still needed. By synthesizing the existing literature, this review seeks to offer novel insights and identify potential therapeutic targets, thereby advancing clinical applications for ocular disease treatment.
No takes yet. Share an insight, caveat, or question.
Sizhen Li (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: